649 METHANOGENIC ARCHAEA AND FUNCTIONAL PATHWAYS SHOW DIFFERENT CORRELATIONS TO THE SEVERITY OF CONSTIPATION IN IBS
Read More →
Maggio 2024
Risultati per: Trattamento della sindrome dell'intestino irritabile (IBS)
Questo è quello che abbiamo trovato per te
Tu1664 EFFECT OF BIFFIDOBACTERIUM BIFFIDUM G9-1 ON THE INTESTINAL ENVIRONMENT AND DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)-LIKE SYMPTOM IN PATIENTS WITH QUIESCENT WITH CROHN'S DISEASE : A PROSPECTIVE INTERNENTION STUDY
Read More →
Maggio 2024
Tu1657 EFFECT OF MICROBIOTA MODULATION WITH RIFAXIMIN IN THE SEVERITY OF FIBROMYALGIA SYMPTOMS, IN PATIENTS WITH AND WITHOUT IBS. AN EXPLORATORY BEFORE AND AFTER STUDY
Read More →
Maggio 2024
Tu1654 MACRONUTRIENT AND FODMAP INTAKE IN RELATION TO SYMPTOM SEVERITY IN IBS PATIENTS FOLLOWING THE LOW FODMAP DIET
Read More →
Maggio 2024
Tu1645 DIFFERENTIAL PATTERNS AND BENEFIT OF IBS-D MEDICATION USE IN SURGICALLY NAIVE PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS
Read More →
Maggio 2024
Tu1660 POINT OF CARE, NON INVASIVE BOWEL SOUND ANALYSIS CORRELATES WITH IBS SYMPTOM SEVERITY
Read More →
Maggio 2024
Tu1690 MODULATION OF INTESTINAL MICROBIOTA AS A LEADING FACTOR IN THE PATHOGENESIS OF IBS
Read More →
Maggio 2024
Tu1672 RIFAXIMIN WITH N-ACETYLCYSTEINE (NAC) IS SUPERIOR TO RIFAXIMIN ALONE IN A RAT MODEL OF IBS-D: A RANDOMIZED CONTROLLED TRIAL
Read More →
Maggio 2024
Mo1894 A MULTI-SPECIES SYNBIOTIC (DS-01) ALLEVIATES CONSTIPATION AND ABDOMINAL PAIN IN IRRITABLE BOWEL SYNDROME SUBTYPE MIXED (IBS-M) SUBJECTS WHILE BOOSTING SYNBIOTIC SPECIES ASSOCIATED WITH DECREASED SYSTEMIC INFLAMMATION AND NET FORMATION
Read More →
Maggio 2024
241 PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY OF EFFICACY OF RIFAMYCIN SV-MMX® 600 MG ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)
Read More →
Maggio 2024
242 EFFICACY OF A NOVEL, DISCRIMATORY P-VALUE BASED, IGG ASSAYGUIDED ELIMINATION DIET BY IBS SUBTYPE: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED STUDY
Read More →
Maggio 2024
Tu1658 EFFICACY OF TENAPANOR IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A POST HOC ANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR USE OF OTHER IBS-C PRESCRIPTION MEDICATIONS FROM THE PHASE 3 T3MPO-1 AND T3MPO-2 STUDIES
Read More →
Maggio 2024
14 PAIN-REDUCTION EFFECT OF A RATIONALLY-DESIGNED LIVE BACTERIAL CONSORTIUM FOR TREATMENT OF IBS BASED ON MICROBIOME FUNCTIONAL GENOMICS ANALYSIS
Read More →
Maggio 2024
Tu1027 ASSESSING US HEALTHCARE DISPARITIES IN IBS DIAGNOSIS: A NATIONAL SURVEY ANALYSIS
Read More →
Maggio 2024
Tu1670 BACTERIAL LYSOPHOSPHATIDYLCHOLINE (LPC) AND LYSOPHOSPHATIDIC ACID (LPA) INDUCE VISCERAL HYPERSENSITIVITY AND LOW-GRADE COLONIC INFLAMMATION IN IRRITABLE BOWEL SYNDROME (IBS)
Read More →
Maggio 2024
Tu1689 CHANGES IN EDN LEVELS IN IBS PATIENTS AFTER FOLLOWING A DIET, BUT NOT AFTER MEDICAL THERAPY
Read More →
Maggio 2024
